These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26250462)

  • 1. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
    Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
    Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
    Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
    Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
    Ghafouri H; Ghaderi B; Amini S; Nikkhoo B; Abdi M; Hoseini A
    Tumour Biol; 2016 Jun; 37(6):7901-6. PubMed ID: 26700668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
    Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
    Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
    Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
    Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
    Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
    Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
    Malhotra H; Sharma P; Malhotra B; Bhargava S; Jasuja S; Kumar M
    Indian J Med Res; 2015 Aug; 142(2):175-82. PubMed ID: 26354214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients.
    Dhangar S; Shanbhag V; Shanmukhaiah C; Vundinti BR
    Mol Biol Rep; 2019 Oct; 46(5):4997-5003. PubMed ID: 31286393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Med Oncol; 2015 Aug; 32(8):213. PubMed ID: 26143137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
    Ali MA; Elsalakawy WA
    Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
    Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
    Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of
    Dalle Fratte C; Polesel J; Gagno S; Posocco B; De Mattia E; Roncato R; Orleni M; Puglisi F; Guardascione M; Buonadonna A; Toffoli G; Cecchin E
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
    Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
    Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.